The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases
Open accessAbstract
The B cell-stimulating molecules, BAFF (B cell activating factor) and APRIL (a proliferation-inducing ligand), are critical factors in the maintenance of the B cell pool and humoral immunity. In addition, BAFF and APRIL are involved in the pathogenesis of a number of human autoimmune diseases, with elevated levels of these cytokines detected in the sera of patients with systemic lupus erythematosus (SLE), IgA nephropathy, Sjögren's syndrome, and rheumatoid arthritis. As such, both molecules are rational targets for new therapies in B cell-driven autoimmune diseases, and several inhibitors of BAFF or BAFF and APRIL together have been investigated in clinical trials. These include the BAFF/APRIL dual inhibitor, atacicept, and the BAFF inhibitor, belimumab, which is approved as an add-on therapy for patients with active SLE. Post hoc analyses of these trials indicate that baseline serum levels of BAFF and BAFF/APRIL correlate with treatment response to belimumab and atacicept, respectively, suggesting a role for the two molecules as predictive biomarkers. It will, however, be important to refine future testing to identify active forms of BAFF and APRIL in the circulation, as well as to distinguish between homotrimer and heteromer configurations. In this review, we discuss the rationale for dual BAFF/APRIL inhibition versus single BAFF inhibition in autoimmune disease, by focusing on the similarities and differences between the physiological and pathogenic roles of the two molecules. A summary of the preclinical and clinical data currently available is also presented.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
γ-secretase directly sheds the survival receptor BCMA from plasma cells
Laurent, S. A., Hoffmann, F. S., Kuhn, P.-H., Cheng, Q., Chu, Y., Schmidt-Supprian, M., Hauck, S. M., Schuh, E., Krumbholz, M., Rübsamen, H., et al. (2015) · Nature Communications · doi:10.1038/ncomms8333 · Cited by 377
Jonsson, M. V., Szodoray, P., Jellestad, S., Jonsson, R., & Skarstein, K. (2005) · Journal of Clinical Immunology · doi:10.1007/s10875-005-4091-5 · Cited by 229
Cited by
Dutertre, C.-A., Becht, E., Irac, S. E., Khalilnezhad, A., Narang, V., Khalilnezhad, S., Ng, P. Y., van den Hoogen, L. L., Leong, J. Y., Lee, B., et al. (2019) · Immunity · doi:10.1016/j.immuni.2019.08.008 · Cited by 520
Adaptive immunity: an emerging player in the progression of NAFLD
Sutti, S., & Albano, E. (2020) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-019-0210-2 · Cited by 374
Baker, K. F., & Isaacs, J. D. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211555 · Cited by 370
Huang, Z., Chen, B., Liu, X., Li, H., Xie, L., Gao, Y., Duan, R., Li, Z., Zhang, J., Zheng, Y., et al. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2023216118 · Cited by 247
New strategies and perspectives on managing IgA nephropathy
Selvaskandan, H., Cheung, C. K., Muto, M., & Barratt, J. (2019) · Clinical and Experimental Nephrology · doi:10.1007/s10157-019-01700-1 · Cited by 83
Metadata
- Authors
- Samy, E., Wax, S., Huard, B., Hess, H., & Schneider, P.
- Venue
- International Reviews of Immunology
- Publisher
- Informa UK Limited
- Published
- 2017-01-02
- Volume
- 36
- Issue
- 1
- Pages
- 3-19
- ISSN
- 0883-0185 (ISSN-L)
- 1563-5244
- OpenAlex
- W2588655590
- Cited by
- 220
- References
- 2
- FWCI
- 11.63
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. https://app.cochat.ai/papers/10.1080/08830185.2016.1276903
- The paper
- Samy, E., Wax, S., Huard, B., Hess, H., & Schneider, P. (2017). Targeting BAFF and APRIL in systemic lupus erythematosus and other antibody-associated diseases. International Reviews of Immunology. https://doi.org/10.1080/08830185.2016.1276903
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.